Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
Gene therapy combined with radiation has shown promising potential for the treatment of tumors. This paper aimed to clarify the synergistic effect of radiotherapy combined with the bladder cancer tissue-specific oncolytic adenovirus (Ad-PSCAE-UPII-E1A) on bladder cancer cells and to study the underlying synergy mechanisms of the combined treatment.



The Adenovirus carrying E1A under control of UPII promoter and prostate stem cell antigen enhancer (PSCAE) were successfully constructed. The viability of bladder cancer cells BIU-87 and EJ was determined by MTT assay. The apoptotic assay was demonstrated by flow cytometry and TEM. Virus titer was determined by TCID50 assay, and proteins Mre11, Chk2-Thr68, and E1A were analyzed by Western blot method.



Oncolytic adenovirus combined with radiotherapy improved antitumor efficacy compared with the single treatment at a time and was X-ray dosage-dependent. When the adenovirus infection was scheduled at 24 h after irradiation, cancer cells had the lowest viability. Adenovirus and irradiation induced cell death through the caspase-3 related apoptotic pathway, and bladder cancer cells were arrested at the G1 (BIU-87) or S phase (EJ). Autophagic vacuoles were observed in bladder cancer cells treated with radiation and adenovirus. After irradiation, more virus particles were observed in the BIU-87 and EJ cells. However, by a TCID50 assay, there was no difference in virus titter between irradiated bladder cancer cells and unirradiated cells. The proteins Mre11, Chk2-Thr68 which involved in the DNA break repair pathway were decreased while γ-H2AX-Ser139 increased; at the same time, the E1A gene and the hexon proteins of oncolytic adenovirus were increased after irradiation.



Our results proved synergistic antitumor effect of adenovirus Ad-PSCAE-UPII-E1A and radiation, which might be a potential therapeutic strategy for bladder cancer.
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.|b The Second Hospital of Tianjin Medical University , Tian Jin , China.
Hongjuan
H
Zhang
c School of Basic Medical Sciences, Lanzhou University , Lanzhou , China.
Fang
F
Wang
d The General Hospital of Tianjin Medical University , Tian Jin , China.
Chunjie
C
Mao
b The Second Hospital of Tianjin Medical University , Tian Jin , China.
Zuncheng
Z
Zhang
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Shengjun
S
Fu
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Jianzhong
J
Lu
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Zhenxing
Z
Zhai
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Renju
R
Li
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Shuwen
S
Li
e Department of Urology , University of Texas Health Science Center , San Antonio , Texas , USA.
Ron
R
Rodriguez
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.
Zhiping
Z
Wang
D000256:Adenoviridae / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000528:radiation effects*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D020266:Radiotherapy, Conformal / Q000379:methods*; D011995:Recombination, Genetic / Q000235:genetics; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy* / Q000821:virology*
Bladder cancer; gene therapy; oncolytic adenovirus; radiation therapy